Integer to Highlight Innovations in Neuromodulation, Next Generation of Miniaturized Active Implantable Devices During NANS 2025 Annual Meeting
Integer Holdings (NYSE: ITGR), a leading medical device contract development and manufacturing organization, will showcase its innovations at the North American Neuromodulation Society (NANS) Annual Meeting from January 30 to February 1, 2025, in Orlando, Florida. At booth #213, Integer will present its latest advancements in neuromodulation and miniaturized active implantable medical devices (AIMDs).
The company will highlight its Xcellion® Gen 3 Fast Charge (FC) Lithium Ion implantable battery technology, which offers industry-leading battery runtime and can fully recharge in as little as 30 minutes. Integer aims to demonstrate its capabilities as a strategic partner for OEMs, focusing on accelerating and de-risking the path to market for novel implantable medical devices through their expertise in critical implantable technologies.
Integer Holdings (NYSE: ITGR), un'importante organizzazione di sviluppo e produzione di dispositivi medici, presenterà le sue innovazioni al North American Neuromodulation Society (NANS) Annual Meeting che si terrà dal 30 gennaio al 1 febbraio 2025 a Orlando, Florida. Presso lo stand #213, Integer mostrerà i suoi ultimi progressi nella neuromodulazione e nei dispositivi medici impiantabili attivi miniaturizzati (AIMDs).
La società evidenzierà la sua tecnologia di batteria impiantabile Xcellion® Gen 3 Fast Charge (FC) a ioni di litio, che offre un'autonomia della batteria leader nel settore e può ricaricarsi completamente in appena 30 minuti. Integer si propone di dimostrare le proprie capacità come partner strategico per gli OEM, concentrandosi sulla accelerazione e riduzione dei rischi nel percorso verso il mercato per nuovi dispositivi medici impiantabili grazie alla loro esperienza nelle tecnologie impiantabili critiche.
Integer Holdings (NYSE: ITGR), una organización líder en el desarrollo y fabricación de dispositivos médicos, presentará sus innovaciones en el North American Neuromodulation Society (NANS) Annual Meeting que se llevará a cabo del 30 de enero al 1 de febrero de 2025 en Orlando, Florida. En el stand #213, Integer mostrará sus últimos avances en neuromodulación y dispositivos médicos implantables activos miniaturizados (AIMDs).
La empresa resaltará su tecnología de batería implantable Xcellion® Gen 3 Fast Charge (FC) de iones de litio, que ofrece una duración de batería líder en la industria y puede recargarse por completo en tan solo 30 minutos. Integer busca demostrar sus capacidades como socio estratégico para los OEM, enfocándose en acelerar y reducir el riesgo en el camino al mercado de nuevos dispositivos médicos implantables a través de su experiencia en tecnologías implantables críticas.
Integer Holdings (NYSE: ITGR)는 의료기기 계약 개발 및 제조 전문 기업으로서, 2025년 1월 30일부터 2월 1일까지 플로리다 주 올랜도에서 열리는 North American Neuromodulation Society (NANS) Annual Meeting에서 혁신 기술을 선보일 예정입니다. 부스 #213에서 Integer는 신경조절 및 미니어처 활성 이식 의료 기기(AIMD) 분야의 최신 발전 사항을 소개합니다.
이 회사는 산업 최고의 배터리 사용 시간을 제공하며, 단 30분 만에 완전히 충전할 수 있는 Xcellion® Gen 3 Fast Charge (FC) 리튬 이온 이식 배터리 기술을 강조할 것입니다. Integer는 OEM을 위한 전략적 파트너로서의 역량을 보여주고, 중요한 이식 기술에 대한 전문성을 통해 혁신적인 이식 의료 기기의 시장 진입 경로를 가속화하고 리스크를 줄이는 데 주력할 계획입니다.
Integer Holdings (NYSE: ITGR), une organisation leader dans le développement et la fabrication de dispositifs médicaux, présentera ses innovations lors du North American Neuromodulation Society (NANS) Annual Meeting qui se tiendra du 30 janvier au 1er février 2025 à Orlando, Floride. Au stand #213, Integer présentera ses dernières avancées en neuromodulation et dans les dispositifs médicaux implantables actifs miniaturisés (AIMDs).
La société mettra en avant sa technologie de batterie implantable Xcellion® Gen 3 Fast Charge (FC) au lithium-ion, qui offre une autonomie de batterie leader dans l'industrie et peut se recharger complètement en seulement 30 minutes. Integer vise à démontrer ses capacités en tant que partenaire stratégique pour les OEM, en se concentrant sur l'accélération et la réduction des risques pour amener sur le marché de nouveaux dispositifs médicaux implantables grâce à son expertise en technologies implantables critiques.
Integer Holdings (NYSE: ITGR), eine führende Organisation für die Entwicklung und Herstellung von Medizinprodukten, wird ihre Innovationen auf dem North American Neuromodulation Society (NANS) Annual Meeting präsentieren, das vom 30. Januar bis 1. Februar 2025 in Orlando, Florida, stattfindet. Am Stand #213 wird Integer seine neuesten Fortschritte in der Neuromodulation und miniaturisierten aktiven implantierbaren medizinischen Geräten (AIMDs) vorstellen.
Das Unternehmen wird seine Xcellion® Gen 3 Fast Charge (FC) Lithium-Ionen-Batterietechnologie hervorheben, die eine branchenführende Batterielaufzeit bietet und in nur 30 Minuten vollständig aufgeladen werden kann. Integer beabsichtigt, seine Fähigkeiten als strategischer Partner für OEMs zu demonstrieren und sich auf die Beschleunigung und Risikominderung beim Marktzugang für neuartige implantierbare Medizinprodukte durch ihre Expertise in kritischen implantierbaren Technologien zu konzentrieren.
- Showcasing advanced Xcellion® Gen 3 FC battery technology with 30-minute full recharge capability
- Strategic positioning in the growing neuromodulation market
- None.
~ Attendees Invited to Visit Integer at Booth #213 ~
PLANO, Texas, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, will join global medtech leaders and innovators in exhibiting at the North American Neuromodulation Society (NANS) Annual Meeting in Orlando, Florida, from Jan. 30 – Feb. 1, 2025.
NANS attendees are invited to visit booth #213 to learn more about how Integer can serve as a strategic partner of choice in amplifying customers’ innovation and increasing speed to market. More specifically, Integer will showcase its latest innovations and expanded capabilities in neuromodulation to enable the next generation of miniaturized active implantable medical devices (AIMDs).
“Through miniaturization, Integer is creating the next generation of differentiated platform technologies to accelerate and de-risk OEMs’ path to market for novel implantable medical devices,” said Jim Stephens, President, Cardiac Rhythm Management & Neuromodulation. “Our broad expertise in critical implantable technologies—from batteries to fully integrated implantable pulse generator systems—uniquely positions Integer to deliver advancements in miniaturized AIMD technologies and help enable our customers’ future therapies. We look forward to discussing this and more at NANS.”
During NANS, attendees can also learn more about Integer’s Xcellion® Gen 3 Fast Charge (FC) Lithium Ion implantable battery technology. Xcellion Gen 3 FC delivers best in class battery runtime and full re-charges in as little as 30 minutes.
Learn more about Integer at www.integer.net.
About Integer®
Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, the Company is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The Company's brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net.
| Investor Relations: | Media Relations: |
| Andrew Senn | Kelly Butler |
| andrew.senn@integer.net | kelly.butler@integer.net |
| 763.951.8312 | 469.731.6617 |
FAQ
What new technology will Integer (ITGR) showcase at NANS 2025?
When and where is Integer (ITGR) presenting at NANS 2025?
What are the key features of Integer's (ITGR) Xcellion Gen 3 FC battery?
How is Integer (ITGR) supporting OEM medical device development?
